Literature DB >> 25685989

Transplanted Umbilical Cord Mesenchymal Stem Cells Modify the In Vivo Microenvironment Enhancing Angiogenesis and Leading to Bone Regeneration.

Maria Rosa Todeschi1, Rania El Backly1,2, Chiara Capelli3, Antonio Daga4, Eugenio Patrone5, Martino Introna3, Ranieri Cancedda1,4, Maddalena Mastrogiacomo1,4.   

Abstract

Umbilical cord mesenchymal stem cells (UC-MSCs) show properties similar to bone marrow mesenchymal stem cells (BM-MSCs), although controversial data exist regarding their osteogenic potential. We prepared clinical-grade UC-MSCs from Wharton's Jelly and we investigated if UC-MSCs could be used as substitutes for BM-MSCs in muscoloskeletal regeneration as a more readily available and functional source of MSCs. UC-MSCs were loaded onto scaffolds and implanted subcutaneously (ectopically) and in critical-sized calvarial defects (orthotopically) in mice. For live cell-tracking experiments, UC-MSCs were first transduced with the luciferase gene. Angiogenic properties of UC-MSCs were tested using the mouse metatarsal angiogenesis assay. Cell secretomes were screened for the presence of various cytokines using an array assay. Analysis of implanted scaffolds showed that UC-MSCs, contrary to BM-MSCs, remained detectable in the implants for 3 weeks at most and did not induce bone formation in an ectopic location. Instead, they induced a significant increase of blood vessel ingrowth. In agreement with these observations, UC-MSC-conditioned medium presented a distinct and stronger proinflammatory/chemotactic cytokine profile than BM-MSCs and a significantly enhanced angiogenic activity. When UC-MSCs were orthotopically transplanted in a calvarial defect, they promoted increased bone formation as well as BM-MSCs. However, at variance with BM-MSCs, the new bone was deposited through the activity of stimulated host cells, highlighting the importance of the microenvironment on determining cell commitment and response. Therefore, we propose, as therapy for bone lesions, the use of allogeneic UC-MSCs by not depositing bone matrix directly, but acting through the activation of endogenous repair mechanisms.

Entities:  

Mesh:

Year:  2015        PMID: 25685989      PMCID: PMC4499786          DOI: 10.1089/scd.2014.0490

Source DB:  PubMed          Journal:  Stem Cells Dev        ISSN: 1547-3287            Impact factor:   3.272


  59 in total

1.  The role of bFGF on the ability of MSC to activate endogenous regenerative mechanisms in an ectopic bone formation model.

Authors:  Roberta Tasso; Massimiliano Gaetani; Erica Molino; Angela Cattaneo; Massimiliano Monticone; Angela Bachi; Ranieri Cancedda
Journal:  Biomaterials       Date:  2011-12-09       Impact factor: 12.479

2.  Comparison of chemokine and receptor gene expression between Wharton's jelly and bone marrow-derived mesenchymal stromal cells.

Authors:  Sudha Balasubramanian; Parvathy Venugopal; Swathi Sundarraj; Zubaidah Zakaria; Anish Sen Majumdar; Malancha Ta
Journal:  Cytotherapy       Date:  2011-11-18       Impact factor: 5.414

3.  Growth and differentiation properties of mesenchymal stromal cell populations derived from whole human umbilical cord.

Authors:  Ingrida Majore; Pierre Moretti; Frank Stahl; Ralf Hass; Cornelia Kasper
Journal:  Stem Cell Rev Rep       Date:  2011-03       Impact factor: 5.739

4.  Short-time survival and engraftment of bone marrow stromal cells in an ectopic model of bone regeneration.

Authors:  Paolo Giannoni; Silvia Scaglione; Antonio Daga; Cristina Ilengo; Michele Cilli; Rodolfo Quarto
Journal:  Tissue Eng Part A       Date:  2010-02       Impact factor: 3.845

5.  The osteogenic differentiation of adult bone marrow and perinatal umbilical mesenchymal stem cells and matrix remodelling in three-dimensional collagen scaffolds.

Authors:  Rebekka K Schneider; Andrea Puellen; Rafael Kramann; Kerstin Raupach; Jörg Bornemann; Ruth Knuechel; Alberto Pérez-Bouza; Sabine Neuss
Journal:  Biomaterials       Date:  2009-10-07       Impact factor: 12.479

6.  Osteoblastic differentiation of Wharton jelly biopsy specimens and their mesenchymal stromal cells after serum-free culture.

Authors:  Andreas A Mueller; Nico Forraz; Sinan Gueven; Gianluigi Atzeni; Olivier Degoul; Aurélie Pagnon-Minot; Daniel Hartmann; Ivan Martin; Arnaud Scherberich; Colin McGuckin
Journal:  Plast Reconstr Surg       Date:  2014-07       Impact factor: 4.730

7.  Opinion of the EMEA on the potential risk associated with medicinal products in relation to bovine spongiform encephalopathy (BSE) (16 April 1996) and report from the Committee for Proprietary Medicinal Products (CPMP) on the 'Note for Guidance on minimizing the risk of transmitting animal spongiform encephalopathies via medicinal products' (15 April 1997).

Authors: 
Journal:  Adverse Drug React Toxicol Rev       Date:  1997-06

8.  Human Wharton's jelly stem cells have unique transcriptome profiles compared to human embryonic stem cells and other mesenchymal stem cells.

Authors:  Chui-Yee Fong; Li-Ling Chak; Arijit Biswas; Jee-Hian Tan; Kalamegam Gauthaman; Woon-Khiong Chan; Ariff Bongso
Journal:  Stem Cell Rev Rep       Date:  2011-03       Impact factor: 5.739

9.  Minimally manipulated whole human umbilical cord is a rich source of clinical-grade human mesenchymal stromal cells expanded in human platelet lysate.

Authors:  Chiara Capelli; Elisa Gotti; Marina Morigi; Cinzia Rota; Ling Weng; Francesco Dazzi; Orietta Spinelli; Giovanni Cazzaniga; Rosangela Trezzi; Andrea Gianatti; Alessandro Rambaldi; Josee Golay; Martino Introna
Journal:  Cytotherapy       Date:  2011-03-18       Impact factor: 5.414

10.  Different populations and sources of human mesenchymal stem cells (MSC): A comparison of adult and neonatal tissue-derived MSC.

Authors:  Ralf Hass; Cornelia Kasper; Stefanie Böhm; Roland Jacobs
Journal:  Cell Commun Signal       Date:  2011-05-14       Impact factor: 5.712

View more
  27 in total

1.  A mouse model for the study of transplanted bone marrow mesenchymal stem cell survival and proliferation in lumbar spinal fusion.

Authors:  Ioan A Lina; Wataru Ishida; Jason A Liauw; Sheng-Fu L Lo; Benjamin D Elder; Alexander Perdomo-Pantoja; Debebe Theodros; Timothy F Witham; Christina Holmes
Journal:  Eur Spine J       Date:  2018-12-03       Impact factor: 3.134

Review 2.  Current and future uses of skeletal stem cells for bone regeneration.

Authors:  Guo-Ping Xu; Xiang-Feng Zhang; Lu Sun; Er-Man Chen
Journal:  World J Stem Cells       Date:  2020-05-26       Impact factor: 5.326

3.  Human umbilical cord blood-borne fibroblasts contain marrow niche precursors that form a bone/marrow organoid in vivo.

Authors:  Alice Pievani; Benedetto Sacchetti; Alessandro Corsi; Benedetta Rambaldi; Samantha Donsante; Valeria Scagliotti; Patrizia Vergani; Cristina Remoli; Andrea Biondi; Pamela G Robey; Mara Riminucci; Marta Serafini
Journal:  Development       Date:  2017-03-15       Impact factor: 6.868

4.  Human Umbilical Cord Mesenchymal Stem Cell-Derived Extracellular Vesicles Carrying MicroRNA-181c-5p Promote BMP2-Induced Repair of Cartilage Injury through Inhibition of SMAD7 Expression.

Authors:  Qiang Zhang; Le Cao; Shanqi Zou; Yuanling Feng; Xudong Miao; Lu Huang; Yongping Wu
Journal:  Stem Cells Int       Date:  2022-06-24       Impact factor: 5.131

5.  Experimental study of vein subvolution combined with neural stem cells to repair sciatic neurologic defects in rats.

Authors:  Kang Li; Yan Jiang; Dianming Jiang
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

6.  Fat-Derived Stromal Vascular Fraction Cells Enhance the Bone-Forming Capacity of Devitalized Engineered Hypertrophic Cartilage Matrix.

Authors:  Atanas Todorov; Matthias Kreutz; Alexander Haumer; Celeste Scotti; Andrea Barbero; Paul E Bourgine; Arnaud Scherberich; Claude Jaquiery; Ivan Martin
Journal:  Stem Cells Transl Med       Date:  2016-07-26       Impact factor: 6.940

Review 7.  Radio-resistant mesenchymal stem cells: mechanisms of resistance and potential implications for the clinic.

Authors:  Nils H Nicolay; Ramon Lopez Perez; Rainer Saffrich; Peter E Huber
Journal:  Oncotarget       Date:  2015-08-14

Review 8.  Patient-Specific Age: The Other Side of the Coin in Advanced Mesenchymal Stem Cell Therapy.

Authors:  Magdalena M Schimke; Sabrina Marozin; Günter Lepperdinger
Journal:  Front Physiol       Date:  2015-12-02       Impact factor: 4.566

9.  Allogeneic Umbilical Cord-Derived Mesenchymal Stem Cells as a Potential Source for Cartilage and Bone Regeneration: An In Vitro Study.

Authors:  A Marmotti; S Mattia; F Castoldi; A Barbero; L Mangiavini; D E Bonasia; M Bruzzone; F Dettoni; R Scurati; G M Peretti
Journal:  Stem Cells Int       Date:  2017-11-16       Impact factor: 5.443

10.  Succinate promotes stem cell migration through the GPR91-dependent regulation of DRP1-mediated mitochondrial fission.

Authors:  So Hee Ko; Gee Euhn Choi; Ji Young Oh; Hyun Jik Lee; Jun Sung Kim; Chang Woo Chae; Diana Choi; Ho Jae Han
Journal:  Sci Rep       Date:  2017-10-03       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.